Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients

Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients: A Randomized Controlled Trial.

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04497649

Enrollment

100

Registered

2020-08-04

Start date

2020-07-01

Completion date

2021-04-10

Last updated

2020-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

efficacy and safety of Sofosbuvir containing regimens in treatment of COVID-19 Egyptian patients,

Detailed description

The study aims to assess Sofosbuvir containing regimens in treatment of COVID-19 Egyptian patients,

Interventions

DRUGSofosbuvir

Sofosbuvir once daily

DRUGDaclatasvir

daclatasuvir once daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* COVID 19 positive patients

Exclusion criteria

* COVID-19 patients with critical manifestations. * Sepsis. * Acute respiratory distress syndrome (ARDS). * Decompensated liver disease (Child-Pugh class B or C disease). * Chronic renal impairment. * Patients with blood diseases (severe anemia, thalassemia, ITP, leukemia ….). * Ischemic heart disease within the last 6 months. * Chronic pulmonary disease. * Malignancy. * Pregnancy or breastfeeding. * Hypersensitivity to sofosbuvir or ribavirin. * Patients with organ transplant. * Unwilling to participate in our study

Design outcomes

Primary

Measure	Time frame	Description
Number of patients with improvement or mortality	1 month	The number of patients with improvement or mortality

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, ass. prof.

sheriefabdelsalam@yahoo.com00201147773440

Backup Contactsherief abd-elsalan, ass. prof.